It will be important to evaluate the expression of Gal3 in circulating tumor cells, and its role as a predictive biomarker in determining response to therapy and DSS and OS in prospective clinical trials in a variety of breast cancer patients. The gene discussed is LGALS3; the disease is breast carcinoma.